Brind.
  1. Acadia Pharmaceuticals, based in San Diego, was the subject of a Zacks analyst survey regarding earnings on August 7, 2025.

Acadia Pharmaceuticals and Genmab A/S Sponsored ADR were analyzed for value investment potential on August 1, 2025.

1 report, 1 independent Updated Aug 1
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Acadia Pharmaceuticals and Genmab A/S Sponsored ADR were analyzed for value investment potential on August 1, 2025.

Who's involved

What this event is mainly about
Acadia Pharmaceuticals

Keep exploring

Part of

Acadia Pharmaceuticals, based in San Diego, was the subject of a Zacks analyst survey regarding earnings on August 7, 2025. All 1 developments

The entities involved

  • Acadia Pharmaceuticals

    Pharmaceutical company, which developed Nuplazid, based in San Diego, California.

    Nothing else this week.

Related events

Coverage

Newest first; wire copies grouped
  • ZacksGMAB vs. ACAD: Which Stock Is the Better Value Option? Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Genmab A/S Sponsored ADR (GMAB) and Acadia P